AR113534A1 - Formulación - Google Patents

Formulación

Info

Publication number
AR113534A1
AR113534A1 ARP180103417A ARP180103417A AR113534A1 AR 113534 A1 AR113534 A1 AR 113534A1 AR P180103417 A ARP180103417 A AR P180103417A AR P180103417 A ARP180103417 A AR P180103417A AR 113534 A1 AR113534 A1 AR 113534A1
Authority
AR
Argentina
Prior art keywords
formulation
polysorbate
glycine
binds
antibody
Prior art date
Application number
ARP180103417A
Other languages
English (en)
Inventor
Andrew Jeffrey Yates
Sandrine Durran
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of AR113534A1 publication Critical patent/AR113534A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente se refiere a composiciones farmacéuticas que comprenden un anticuerpo o un fragmento de este que se une a IL-17A e IL-17F y una combinación de glicina, tampón acetato a pH 4,6 a 5,5 y polisorbato 80.
ARP180103417A 2017-11-23 2018-11-22 Formulación AR113534A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1719447.3A GB201719447D0 (en) 2017-11-23 2017-11-23 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
AR113534A1 true AR113534A1 (es) 2020-05-13

Family

ID=60950516

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103417A AR113534A1 (es) 2017-11-23 2018-11-22 Formulación

Country Status (19)

Country Link
US (2) US11857625B2 (es)
EP (1) EP3713602A1 (es)
JP (1) JP6955632B2 (es)
KR (1) KR20200090829A (es)
CN (1) CN111511399A (es)
AR (1) AR113534A1 (es)
AU (1) AU2018371056A1 (es)
BR (1) BR112020009866A2 (es)
CA (1) CA3082832C (es)
CL (1) CL2020001307A1 (es)
CO (1) CO2020006120A2 (es)
EA (1) EA202091295A1 (es)
GB (1) GB201719447D0 (es)
IL (1) IL274719A (es)
MX (1) MX2020004747A (es)
MY (1) MY194682A (es)
RU (1) RU2020120547A (es)
SG (1) SG11202004601YA (es)
WO (1) WO2019101582A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
CN113769082A (zh) * 2020-06-10 2021-12-10 上海君实生物医药科技股份有限公司 抗il-17a抗体药物组合物及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615122A1 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
GB0620729D0 (en) * 2006-10-18 2006-11-29 Ucb Sa Biological products
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
CN102686241A (zh) 2009-12-29 2012-09-19 霍夫曼-拉罗奇有限公司 抗体配制剂
SI3295957T1 (sl) 2010-01-15 2020-02-28 Kirin-Amgen, Inc. Formulacija protitelesa proti IL-17RA in terapevtski režim za zdravljenje luskavice
CA2794929C (en) 2010-03-01 2018-06-05 Progenics Pharmaceuticals, Inc. Concentrated protein formulations and uses thereof
AU2011250920B2 (en) * 2010-05-14 2015-05-21 Amgen Inc. High concentration antibody formulations
FR2962650B1 (fr) 2010-07-19 2013-04-05 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
SG189138A1 (en) * 2010-11-05 2013-05-31 Novartis Ag Methods of treating rheumatoid arthritis using il-17 antagonists
MA34907B1 (fr) * 2011-01-14 2014-02-01 Ucb Pharma Sa Molécules d'anticorps se liant à il-17a et il-17f
CA2876012A1 (en) * 2012-06-21 2013-12-27 Ucb Pharma S.A. Pharmaceutical formulation
CN107148283A (zh) * 2014-10-31 2017-09-08 豪夫迈·罗氏有限公司 抗il‑17a和il‑17f交叉反应性抗体变体、包含其的组合物及其制备和使用方法
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
HRP20230463T1 (hr) 2015-08-19 2023-07-21 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
CN108350068A (zh) * 2015-10-27 2018-07-31 Ucb生物制药私人有限公司 使用抗-il-17a/f抗体的治疗方法
WO2017180594A1 (en) 2016-04-13 2017-10-19 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
EA201990673A1 (ru) 2016-09-14 2019-08-30 Бэйцзин Ханми Фарм. Ко., Лтд. Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты

Also Published As

Publication number Publication date
CA3082832C (en) 2023-07-18
IL274719A (en) 2020-07-30
BR112020009866A2 (pt) 2020-11-17
CN111511399A (zh) 2020-08-07
RU2020120547A3 (es) 2021-12-23
US11857625B2 (en) 2024-01-02
CO2020006120A2 (es) 2020-05-29
CA3082832A1 (en) 2019-05-31
MY194682A (en) 2022-12-14
KR20200090829A (ko) 2020-07-29
EP3713602A1 (en) 2020-09-30
RU2020120547A (ru) 2021-12-23
US20240123065A1 (en) 2024-04-18
SG11202004601YA (en) 2020-06-29
JP6955632B2 (ja) 2021-10-27
AU2018371056A1 (en) 2020-06-04
CL2020001307A1 (es) 2020-10-16
WO2019101582A1 (en) 2019-05-31
GB201719447D0 (en) 2018-01-10
US20210106683A1 (en) 2021-04-15
EA202091295A1 (ru) 2020-09-03
MX2020004747A (es) 2020-08-20
JP2021504321A (ja) 2021-02-15

Similar Documents

Publication Publication Date Title
AR113534A1 (es) Formulación
CO2018008754A2 (es) Composición farmacéutica que comprende constructos de anticuerpo biespecíficos
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
CO2018009533A2 (es) Conjugados de amanitina
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
CL2013003090A1 (es) Polipeptido que comprende una primera secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17f, il17-a/f, pero no a il-17a, y una segunda secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17a, il-17f y il17-a/f; composicion farmaceutica que lo comprende; y su uso.
WO2016210365A3 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
BR112018010360A2 (pt) fragmentos fab de fator de complemento anti-c1q e utilizações dos mesmos
CO2019002370A2 (es) Anticuerpo que se une específicamente a il-17a y fragmento funcional del mismo
MX2020008219A (es) Formulacion farmaceutica de ph bajo.
CR20190208A (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
CL2019002478A1 (es) Formulación de anticuerpo monoclonal anti-vrs.
EP3865154A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY FAB FRAGMENT COMPLEX AT LABELED ANTI-HUMAN SITE
BR112016026811A2 (pt) formulação de anticorpo
EA202192405A1 (ru) Составы антител против il-36r
BR112018075630A2 (pt) anticorpos anti-cd98 e conjugados de fármaco de anticorpo
CL2020003277A1 (es) Métodos de fabricación de composiciones de aminoácidos
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
BR112021024938A2 (pt) Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
BR112021025438A2 (pt) Composições de proteínas anti-vegf e métodos para produzir as mesmas
EA201992027A1 (ru) Водный состав антитела против pd-l1
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека